Advertisement

Effects of extended-release niacin on lipoprotein subclass distribution

      Abstract

      The efficacy of extended-release niacin (niacin ER) on lipoprotein subclasses was evaluated in patients with primary hypercholesterolemia using a proton nuclear magnetic resonance method. Paired plasma samples collected at baseline and after 12 weeks’ treatment with niacin ER 1,000 (n = 21) or 2,000 (n = 20) mg/day or placebo (n = 19) were available for 60 eligible patients from a previous multicenter, randomized, controlled trial. Niacin ER increased high-density lipoprotein (HDL) cholesterol and decreased low-density lipoprotein (LDL) cholesterol and very low-density lipoprotein triglycerides in a dose-dependent manner relative to placebo. Niacin ER increased large HDL particles (H5 and H4, corresponding to the HDL2ab fraction) without having a net effect on small HDL particles (H3, H2, and H1, corresponding to the HDL3abc fraction). It also decreased smaller, denser LDL particles (L1 and L2) and increased the larger, more buoyant L3 subclass. The inhibitory effect of niacin ER on very low-density lipoprotein was evident on the larger particles (V6, V5, V4, and V3 subclasses) rather than the smaller ones (V2 and V1). The results show that niacin ER produces a beneficial effect on lipoprotein subclasses, specifically decreasing the more atherogenic small, dense LDL particles and enhancing the cardioprotective large HDL particles.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Superko H.R.
        • the Kos Investigators
        Effect of nicotinic acid on LDL subclass patterns (abstr).
        Circulation. 1994; 90: I-504
        • Morgan J.M.
        • Capuzzi D.M.
        • Guyton J.R.
        • Centor R.M.
        • Goldberg R.
        • Robbins D.C.
        • DiPette D.
        • Jenkins S.
        • Marcovina S.
        Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia.
        J Cardiovasc Pharmacol Ther. 1996; 1: 195-202
        • Otvos J.D.
        • Jeyarajah E.J.
        • Bennett D.W.
        • Krauss R.M.
        Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement.
        Clin Chem. 1992; 38: 1632-1638
        • Austin M.A.
        • Breslow J.L.
        • Hennekens C.H.
        • Buring J.E.
        • Willett W.C.
        • Krauss R.M.
        Low-density lipoprotein subclass patterns and risk of myocardial infarction.
        JAMA. 1988; 260: 1917-1921
        • Austin M.A.
        • Rodriguez B.L.
        • McKnight B.
        • McNeely M.J.
        • Edwards K.L.
        • Curb J.D.
        • Sharp D.S.
        Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men.
        Am J Cardiol. 2000; 86: 412-416
        • Gardner C.D.
        • Fortmann S.P.
        • Krauss R.M.
        Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.
        JAMA. 1996; 276: 875-881
        • Lamarche B.
        • Tchernof A.
        • Mauriège P.
        • Cantin B.
        • Dagenais G.R.
        • Lupien P.J.
        • Despres J.-P.
        Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease.
        JAMA. 1998; 279: 1955-1961
        • Lamarche B.
        • St-Pierre A.C.
        • Ruel I.L.
        • Cantin B.
        • Dagenais G.R.
        • Despres J.P.
        A prospective, population-based study of low-density lipoprotein particle size as a risk factor for ischemic heart disease in men.
        Can J Cardiol. 2001; 17: 859-865
        • Campos H.
        • Moye L.A.
        • Glasser S.P.
        • Stampfer M.J.
        • Sacks F.M.
        Low-density lipoprotein size, pravastatin treatment, and coronary events.
        JAMA. 2001; 286: 1468-1474
        • Johansson J.
        • Carlson L.A.
        • Landou C.
        • Hamsten A.
        High density lipoproteins and coronary atherosclerosis.
        Arterioscler Thromb. 1991; 11: 174-182
        • Griffin B.A.
        • Skinner E.R.
        • Maughan R.J.
        Plasma high-density lipoprotein subfractions in subjects with different coronary risk indices as assessed by plasma lipoprotein concentrations.
        Atherosclerosis. 1988; 70: 165-169
        • Kamanna V.S.
        • Kashyap M.L.
        Mechanism of action of niacin on lipoprotein metabolism.
        Curr Atheroscler Rep. 2000; 2: 36-46
        • Kashyap M.L.
        Mechanistic studies of high-density lipoproteins.
        Am J Cardiol. 1998; 82: 42U-48U
        • Tavintharan S.
        • Kashyap M.L.
        The benefits of niacin in atherosclerosis.
        Curr Atheroscler Rep. 2001; 3: 74-82
        • Superko H.R.
        • Krauss R.M.
        Differential effects of nicotinic acid in subjects with different LDL subclass patterns.
        Atherosclerosis. 1992; 95: 69-76
        • McKenney J.M.
        • McCormick L.S.
        • Schaefer E.J.
        • Black D.M.
        • Watkins M.L.
        Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
        Am J Cardiol. 2001; 88: 270-274
        • Zambon A.
        • Hokanson J.E.
        • Brown B.G.
        • Brunzell J.D.
        Evidence for a new pathophysiological mechanism for coronary artery disease regression.
        Circulation. 1999; 99: 1959-1964